NOACs are now the preferred treatment for managing non-valvular atrial fibrillation (NVAFib) and preventing venous thromboembolism (VTE)1p1c. The success of NOACs has also encouraged further research into their potential use in preventing embolic strokes of unknown origin, which account for ~25% of all ischaemic strokes (IS), and reducing CV events in patients with arterial ischaemic diseases.1
AFib is the most prevalent atrial arrhythmia, characterised by abnormal electrical activity in the atria, resulting in rapid and irregular heartbeats. AFib can be...
